WO2000029583A3 - Proteines de la superfamille des immunoglobulines - Google Patents

Proteines de la superfamille des immunoglobulines Download PDF

Info

Publication number
WO2000029583A3
WO2000029583A3 PCT/US1999/027566 US9927566W WO0029583A3 WO 2000029583 A3 WO2000029583 A3 WO 2000029583A3 US 9927566 W US9927566 W US 9927566W WO 0029583 A3 WO0029583 A3 WO 0029583A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin superfamily
igfam
superfamily proteins
provides
expression
Prior art date
Application number
PCT/US1999/027566
Other languages
English (en)
Other versions
WO2000029583A2 (fr
Inventor
Henry Yue
Y Tom Tang
Neil C Corley
Karl J Guegler
Gina A Gorgone
Mariah R Baughn
Dyung Aina M Lu
Preeti Lal
Jennifer L Hillman
Junming Yang
Original Assignee
Incyte Pharma Inc
Henry Yue
Y Tom Tang
Neil C Corley
Karl J Guegler
Gina A Gorgone
Mariah R Baughn
Dyung Aina M Lu
Preeti Lal
Jennifer L Hillman
Junming Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharma Inc, Henry Yue, Y Tom Tang, Neil C Corley, Karl J Guegler, Gina A Gorgone, Mariah R Baughn, Dyung Aina M Lu, Preeti Lal, Jennifer L Hillman, Junming Yang filed Critical Incyte Pharma Inc
Priority to EP99959059A priority Critical patent/EP1131428A2/fr
Priority to JP2000582566A priority patent/JP2002530080A/ja
Priority to AU16310/00A priority patent/AU1631000A/en
Priority to CA002351313A priority patent/CA2351313A1/fr
Publication of WO2000029583A2 publication Critical patent/WO2000029583A2/fr
Publication of WO2000029583A3 publication Critical patent/WO2000029583A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)

Abstract

L'invention concerne des protéines humaines de la superfamille des immunoglobulines (IGFAM) ainsi que des polynucléotides qui identifient et codent pour IGFAM. L'invention concerne également des vecteurs d'expression, des cellules hôtes, des anticorps, des agonistes et des antagonistes. L'invention concerne par ailleurs des méthodes destinées au diagnostic, au traitement ou à la prévention de troubles associés à l'expression de IGFAM.
PCT/US1999/027566 1998-11-19 1999-11-19 Proteines de la superfamille des immunoglobulines WO2000029583A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99959059A EP1131428A2 (fr) 1998-11-19 1999-11-19 Proteines de la superfamille des immunoglobulines
JP2000582566A JP2002530080A (ja) 1998-11-19 1999-11-19 免疫グロブリン・スーパーファミリー・タンパク質
AU16310/00A AU1631000A (en) 1998-11-19 1999-11-19 Immunoglobulin superfamily proteins
CA002351313A CA2351313A1 (fr) 1998-12-22 1999-11-19 Proteines de la superfamille des immunoglobulines

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19585398A 1998-11-19 1998-11-19
US11363598P 1998-12-22 1998-12-22
US60/113,635 1998-12-22
US12819499P 1999-04-07 1999-04-07
US60/128,194 1999-04-07

Publications (2)

Publication Number Publication Date
WO2000029583A2 WO2000029583A2 (fr) 2000-05-25
WO2000029583A3 true WO2000029583A3 (fr) 2000-09-08

Family

ID=27381363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027566 WO2000029583A2 (fr) 1998-11-19 1999-11-19 Proteines de la superfamille des immunoglobulines

Country Status (4)

Country Link
EP (1) EP1131428A2 (fr)
JP (1) JP2002530080A (fr)
AU (1) AU1631000A (fr)
WO (1) WO2000029583A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7198917B2 (en) 1997-11-21 2007-04-03 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
KR100468978B1 (ko) * 1998-12-16 2005-02-02 제넨테크, 인크. 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
CA2382161A1 (fr) * 1999-09-03 2001-03-15 Human Genome Sciences, Inc. Polynucleotides, polypeptides, et anticorps de la superfamille des immunoglobulines
CA2402729A1 (fr) * 2000-03-15 2001-09-20 Incyte Genomics, Inc. Proteines de reponse immunitaire humaines
CA2412610A1 (fr) * 2000-06-23 2002-01-03 Biogen, Inc. Polypeptides et acides nucleiques gp286
AU2001278655A1 (en) * 2000-07-18 2002-01-30 Compugen Ltd. Novel nucleic acid and amino acid sequences
JP2004535759A (ja) * 2000-11-16 2004-12-02 インサイト・ゲノミックス・インコーポレイテッド 免疫グロブリンスーパファミリタンパク質
CA2440618A1 (fr) * 2001-03-12 2002-09-19 Incyte Genomics, Inc. Proteines de la superfamille des immunoglobulines
EP1513867A4 (fr) * 2001-07-16 2006-02-08 Lilly Co Eli Molecules d'adhesion jonctionnelle extracellulaires
US7179606B2 (en) * 2001-11-23 2007-02-20 Syn X Pharma, Inc. IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
WO2005030793A2 (fr) 2003-09-24 2005-04-07 Millennium Pharmaceuticals, Inc. Anticorps se liant aux cxcr3 humains
WO2006078766A2 (fr) * 2005-01-19 2006-07-27 University Of Connecticut Methodes et compositions pour le depistage de tumeurs metastatiques
US20100168382A1 (en) * 2007-06-12 2010-07-01 Vladimir Berezin Neuroplastin derived peptides
PE20141549A1 (es) 2008-05-06 2014-10-25 Genentech Inc VARIANTES DE CRIg MADURAS POR AFINIDAD

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737747A2 (fr) * 1995-04-11 1996-10-16 Behringwerke Ag Expression cytoplasmique dans E. coli des anticorps, fragments d'anticorps et fusions de ceux-ci
WO1997008320A1 (fr) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Banques de proteines/(poly)peptides
WO1997023613A2 (fr) * 1995-12-21 1997-07-03 Celltech Therapeutics Ltd. Procede d'activation de cellules et ses reactifs
WO1997042329A1 (fr) * 1996-05-04 1997-11-13 Zeneca Limited Anticorps monoclonal anti-cea, conjugues contenant cet anticorps et leur utilisation therapeutique dans un systeme adept
WO1997049809A1 (fr) * 1996-06-24 1997-12-31 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Olypeptides capables de former des structures de liaison a l'ant igene avec une specificite pour les antigenes de rhesus d, adn les codant et procede pour leur preparation et leur utilisation
WO1998002462A1 (fr) * 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Domaines de la superfamille des immunoglobulines et fragments presentant une solubilite accrue
WO1998011241A1 (fr) * 1996-09-16 1998-03-19 Merck Patent Gmbh Systeme d'expression oligocistronique destine a la production de proteines heteromeres

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737747A2 (fr) * 1995-04-11 1996-10-16 Behringwerke Ag Expression cytoplasmique dans E. coli des anticorps, fragments d'anticorps et fusions de ceux-ci
WO1997008320A1 (fr) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Banques de proteines/(poly)peptides
WO1997023613A2 (fr) * 1995-12-21 1997-07-03 Celltech Therapeutics Ltd. Procede d'activation de cellules et ses reactifs
WO1997042329A1 (fr) * 1996-05-04 1997-11-13 Zeneca Limited Anticorps monoclonal anti-cea, conjugues contenant cet anticorps et leur utilisation therapeutique dans un systeme adept
WO1997049809A1 (fr) * 1996-06-24 1997-12-31 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Olypeptides capables de former des structures de liaison a l'ant igene avec une specificite pour les antigenes de rhesus d, adn les codant et procede pour leur preparation et leur utilisation
WO1998002462A1 (fr) * 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Domaines de la superfamille des immunoglobulines et fragments presentant une solubilite accrue
WO1998011241A1 (fr) * 1996-09-16 1998-03-19 Merck Patent Gmbh Systeme d'expression oligocistronique destine a la production de proteines heteromeres

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLONNA M ET AL: "CLONING OF IMMUNOGLOBULIN-SUPERFAMILY MEMBERS ASSOCIATED WITH HLA-CAND HLA-B RECOGNITION BY HUMAN NATURAL KILLER CELLS", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 268, 21 April 1995 (1995-04-21), pages 405 - 408, XP002067321, ISSN: 0036-8075 *
DATABASE GENBANK 8 January 1998 (1998-01-08), PATERSON T.: ". sapiens mRNA for immunoglobulin kappa light chain", XP002132529 *
LI S ET AL: "A COMPUTER SCREENING APPROACH TO IMMUNOGLOBULIN SUPERFAMILY STRUCTURES AND INTERACTIONS: DISCOVERY OF SMALL NON-PEPTIDIC CD4 INHIBITORS AS NOVEL IMMUNOTHERAPEUTICS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 94, 1 January 1997 (1997-01-01), pages 73 - 78, XP000619663, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
JP2002530080A (ja) 2002-09-17
WO2000029583A2 (fr) 2000-05-25
EP1131428A2 (fr) 2001-09-12
AU1631000A (en) 2000-06-05

Similar Documents

Publication Publication Date Title
WO1999061471A3 (fr) Proteines transmembranaires humaines
WO2001012662A3 (fr) Proteines associees a la membrane
WO2000015793A3 (fr) Proteines gpcr humaines
WO2000000610A3 (fr) Proteines contenant un peptide signal humain
WO2000022143A3 (fr) Homologues de proteines kinases
WO2000029583A3 (fr) Proteines de la superfamille des immunoglobulines
WO2000018922A3 (fr) Proteines humaines associees a des glucides
WO2000021988A3 (fr) Proteine humaine de la famille des ankyrines
WO2000034477A3 (fr) Proteines associees a des neurones
WO1999058692A3 (fr) Proteines associees a l'apoptose humaine
WO2000012711A3 (fr) Proteines membranaires de canal humaines
WO2000009709A3 (fr) Proteases et proteines associees
WO2000012703A3 (fr) Molecules associees au transport de proteines
WO2000017355A3 (fr) Proteines humaines associees au cytosquelette
WO2001007612A3 (fr) Recepteurs et proteines associees
WO2001005970A3 (fr) Proteines associees de liaison gtp
WO2000014251A3 (fr) Transferases humaines
WO2000052151A3 (fr) Proteines de secretion humaines
WO2002072794A3 (fr) Proteines de la superfamille des immunoglobulines
WO1999058558A3 (fr) Proteines de signalisation cellulaire
WO2000028032A3 (fr) Proteines du recepteur de surface des cellules humaines
WO2000000594A3 (fr) Transferases humaines
WO1999061614A3 (fr) Proteines socs humaines
WO2000031263A3 (fr) Proteines associees a la gtpase
WO2000028045A3 (fr) Hydrolases humaines

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 16310

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09831805

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2351313

Country of ref document: CA

Ref country code: CA

Ref document number: 2351313

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 582566

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999959059

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999959059

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999959059

Country of ref document: EP